NVS and RNA Related Headlines
Go Back- Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal
- Novartis CEO defends $12 billion deal for Avidity as 'appropriate risk to take'
- H.C. Wainwright Downgrades Avidity Biosciences (RNA) to Neutral Post Novartis Acquisition
- Novartis to acquire Avidity Biosciences for $12 billion or $72 per share cash
- Novartis Said To Near Deal $70-per-share-plus Deal For Avidity Biosciences (RNA) - Bloomberg
- Avidity Biosciences stock soars on Novartis takeover approach report
- Novartis (NVS) Made A Takeover Approach Avidity Biosciences (RNA) - FT
